CD274 and ovarian carcinoma: The JAVELIN ovarian 100 (NCT02718417), which combined carboplatin–paclitaxel with avelumab (anti-PD-L1) in previously untreated patients with epithelial ovarian cancer, was interrupted early due to significantly lower PFS in the arm with avelumab as maintenance therapy after chemotherapy (Hazard ratio (HR) of 1.43 with 95% CI of 1.051⌓1.946) [24].